Article Per Year (5 Year)
p-Index From 2019 - 2024
1.288
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran Syiah Kuala Jurnal Profesi Medika: Jurnal Kedokteran dan Kesehatan Farmasains : Jurnal Ilmiah Ilmu Kefarmasian Majalah Farmasi dan Farmakologi (Trends in Pharmacy and Pharmaceutical Sciences) JURNAL ILMU KEFARMASIAN INDONESIA Budapest International Research and Critics Institute-Journal (BIRCI-Journal): Humanities and Social Sciences Jurnal Farmagazine
Yusi Anggriani
Unknown Affiliation
Religion Arts Humanities Biochemistry, Genetics & Molecular Biology Chemistry Economics, Econometrics & Finance Health Professions Immunology & microbiology Medicine & Pharmacology Social Sciences

Published : 8 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 8 Documents
Search

 1 
ANALISIS EFEKTIVITAS BIAYA TERAPI OLANZAPIN DAN KOMBINASI HALOPERIDOL DENGAN DIAZEPAM SECARA INTRAMUSKULAR PADA PASIEN RAWAT INAP SKIZOFRENIA FASE AKUT DI RSKD DUREN SAWIT Desweri Muhareni; Yusi Anggriani; Fredrick Dermawan Purba
Majalah Farmasi dan Farmakologi Vol. 25 No. 1 (2021): MFF
Publisher : Faculty of Pharmacy, Hasanuddin University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20956/mff.v25i1.11561

Abstract

Skizofrenia merupakan gangguan jiwa berat yang dapat mempengaruhi pikiran, perasaan dan perilakuindividu, ditandai dengan hilangnya pemahaman terhadap realitas dan daya tilik diri. Pasien skizofrenia padafase akut dapat diberikan olanzapin injeksi dan kombinasi haloperidol injeksi dan diazepam injeksi secara intramuskular. Harga olanzapin injeksi lebih mahal daripada kombinasi haloperidol injeksi dan diazepam injeksi.Penelitian ini bertujuan untuk melihat biaya rerata medis langsung dan membandingkan denganefektivitasnya. Penelitian ini dilakukan secara kohort prospektif di RSKD Duren Sawit dari Juni – Agustus 2019.Data pasien diambil dari rekam medis, data total biaya langsung medis di ruang akut, nilai PANSS EC pre danpost perawatan di ruang akut. Jumlah total sampel dalam penelitian ini adalah 193 pasien, terdiri atas 102pasien kelompok olanzapin injeksi dan 91 pasien kelompok kombinasi haloperidol injeksi dan diazepam injeksi.Rerata total biaya medis langsung yang diperlukan pasien skizofrenia fase akut dengan olanzapin injeksisebesar Rp 2.446.644±814.719 lebih tinggi dari kombinasi haloperidol injeksi dan diazepam injeksi sebesar Rp1.796.962±408.376,. Rerata selisih PANSS EC pre dan post rawat olanzapin injeksi 16,08 lebih tinggi darikombinasi haloperidol injeksi dan diazepam injeksi sebesar 14,62. Uji Mann Whitney menunjukkan terapiolanzapin injeksi menunjukkan perbaikan yang lebih tinggi untuk perbaikan PANSS EC (p<0,05), tetapi tidakterdapat perbedaan yang bermakna (p>0,05) dalam lama hari rawat (LOS).
ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN ERITROPOETIN (HEMAPO® , EPOTREX®, NEORECORMON®) PADA PASIEN HEMODIALISIS DI RSUP PERSAHABATAN Chandra Widianti; Yusi Anggriani; Tri Kusumaeni; Okpri Meila
Jurnal Kedokteran Syiah Kuala Vol 18, No 3 (2018): Volume 18 Nomor 3 Desember 2018
Publisher : Universitas Syiah Kuala

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24815/jks.v18i3.18017

Abstract

Abstrak. Penerapan INA-CBGs (Indonesia Case Base Groups) di era JKN mendorong penyedia layanan kesehatan, untuk menghitung biaya yang dikeluarkan agar tidak merugi. Pada pasien Gagal Ginjal Kronis (GGK) yang menjalani hemodialisis, prevalensi anemia cukup tinggi, sehingga diberikan eritropoetin (EPO). Dibutuhkan penelitian untuk mengetahui dari beberapa jenis EPO, mana yang lebih cost-effective. Penelitian deskriptif non-eksperimental dilakukan di Unit Hemodialisa Rumah Sakit Persahabatan. Efektivitas terapi ditentukan oleh peningkatan kadar hemoglobin (Hb) setelah 3 (tiga) bulan berturut-turut mendapatkan terapi EPO yang sama. Analisis efektivitas-biaya diperoleh dengan menghitung nilai CER (Cost-Effectiveness Ratio). Hasil menunjukkan penggunaan Neorecormon® memiliki efektivitas yang lebih tinggi dengan persentase jumlah pasien yang mengalami peningkatan Hb sebesar 56,41% dibandingkan Hemapo® (54%) dan Epotrex® (52,63%). Total biaya pengobatan rata-rata dengan Hemapo® , Epotrex® dan Neorecormon® masing-masing Rp. 32.552.117, Rp. 34.787.487 dan Rp. 32.866.969. Hasil perhitungan nilai CER dalam penggunaan Neorecormon® untuk pasien yang mengalami peningkatan Hb adalah Rp 58.264.437, lebih kecil daripada Hemapo® (Rp. 60.281.698) and Epotrex® (Rp. 66.098.208). Berdasarkan nilai CER dan tabel efektivitas-biaya, menunjukkan bahwa Neorecormon® adalah pilihan terapi yang lebih cost-effective daripada Hemapo® dan Epotrex®.Kata-kata kunci: Analisis efektivitas-biaya, hemodialisis, eritropoetinAbstract. INA-CBGs (Indonesia Case Base Groups) in JKN era, encourages health care providers to calculate costs incurred so as not to lose money. In Chronic Renal Failure (CRF) patients who undergo hemodialysis, anemia prevalence is high enough to require administration of erythropoietin (EPO). It’s necessary to investigate the therapeutic treatment from several types of EPO, which is more cost-effective. Descriptive non-experimental research conducted in the Hemodialysis Unit in Persahabatan Hospital. The effectiveness determined by an increased in hemoglobin (Hb) levels after three (3) months earned the same EPO therapy. Cost-effectiveness analysis is obtained by calculated the CER (Cost-Effectiveness Ratio). The results shows that Neorecormon® have a higher effectiveness with the percentage of patients whose Hb level increase by 56.41% comparing to Hemapo® (54%) and Neorecormon® (52.63%). The average total cost with Hemapo®, Epotrex® and Neorecormon® each successive Rp. 32.552.117, Rp. 34.787.487 and Rp. 32.866.969. The CER value of Neorecormon® show cost-effectiveness of Rp 58.264.437 for a patient with an increase in Hb, smaller than Hemapo® (Rp. 60.281.698) and Epotrex® (Rp. 66.098.208). Based on CER value and cost effectiveness grid, shows that Neorecormon® is the choice that is more cost-effective than Hemapo® and Epotrex®. Keywords : Cost effectiveness analysis, hemodialysis, erythropoetin
Analisis Dampak Program Pengelolaan Penyakit Kronis (Prolanis) Dalam Meningkatkan Outcome Klinis Pasien Diabetes Melitus Tipe 2 Di Puskesmas Jakarta, Indonesia Reise Manninda; Yusi Anggriani; Astrid Kartika Sari
JURNAL ILMU KEFARMASIAN INDONESIA Vol 19 No 2 (2021): JIFI
Publisher : Fakultas Farmasi Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35814/jifi.v19i2.1107

Abstract

Prolanis is a Chronic Disease Management Program under the Indonesian National Health Insurance for promoting and preventing chronic disease. Main activities of Prolanis program are disease control and counseling, scheduled education, scheduled exercise, participant’s remainder, and home visit. The aim of this study was to evaluate the impact of prolanis on the clinical outcome in type 2 Diabetes Mellitus (DM) patients. An observational retrospective study was evaluated for 12 months. Data was collected from medical record. 426 patients from five primary health care center in Jakarta was selected by simple random sampling and divided into prolanis and non-prolanis groups. The indicators were the difference of clinical outcome between prolanis and non-prolanis patients was analyzed using Mann-Whitney test; the correlation of adherence with clinical outcome was analyzed using Chi-Square test.The results showed that prolanis patients had a significant improvement in Fasting Blood Glucose (FBG) compared with non-prolanis patients (P<0.05). The adherence of prolanis patients showed a significant improvement on FBG (124 patients-58.2%). Patients with nonadherence had lower improvement on FBG, the improvement was observed only at 16 patients (7.5%) and 60 patients (28.17%) was poor FBG. Prolanis is an effective program to improve the clinical outcome of DM patients.
Analisis Efektivitas Biaya Pengobatan Kombinasi Zidovudin, Lamivudin, Nevirapin dan Kombinasi Tenofovir, Lamivudin, Efavirenz Pada Pasien HIV/AIDS di RSUD Kota Bekasi Yusi Anggriani; Fredrick D. Purba; Reise Manninda; Tarsinah Tarsinah
JURNAL ILMU KEFARMASIAN INDONESIA Vol 18 No 2 (2020): JIFI
Publisher : Fakultas Farmasi Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35814/jifi.v18i2.905

Abstract

HIV/AIDS has become a global issue in many countries. The implementation of ARV / HAARTprograms is always changing, due to clinical reasons, population factors, and aff ordability. Pharmacoeconomic studies can be one of the considerations in the policy process for procurement and selection of therapy regimens. The aims of this study were to determine the eff ectiveness of treatment based on CD4 increase and cost eff ectiveness analysis of HAART A and HAART B treatment regimens. This study used a cross sectional observation method. Retrospective data collection and non-experimental observation where conducted followes by a quantitative descriptive analysis according to the patient's perspective to obtain costeffectiveness data. Data were statistically analyzed to obtain the cost-eff ectiveness of treatment. The results showed that the cost-eff ectiveness analysis (CEA) of two regimens found that HAART A was more dominant than HAART B with a signifi cant diff erence p<0.05. While ACER regimen HAART A (16,227) was greater than the value ACER therapy B (28,330.7).
Profile Evaluation of Medication, Cost Comparison, and Clinical Outcome of Human and Analog Insulin Treatment to Type-2 Diabetes Mellitus Outpatient at Medistra Hospital Year 2012-2013 Elisabeth Ninung Yuliarti; Yusi Anggriani; Dian Ratih Laksmitawati; Prasasta Sutedjo
Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan Vol 14, No 2 (2020): Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan
Publisher : Fakultas Kedokteran UPN Veteran Jakarta Kerja Sama KNPT

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33533/jpm.v14i2.2007

Abstract

The data collection was conducted retrospectively, taking samples of 121 outpatients, of which 83 outpatients were evaluated for their clinical outcome. The medication profile data were collected from the medicine administration at the Hospital Pharmacy Installation. The clinical outcome data, such as fasting plasma glucose (FPG), two-hour postprandial plasma glucose (2HPP), and Hemoglobin A1c (HbA1c), were garnered from the patients’ medical records. The cost data were collected from the outpatients’ payment receipts provided by the Hospital’s Financial Department. Kolmogorov Smirnov normality test was applied in this research. The research result suggests that after Mann Whitney Test, the human and analogue insulin were not significantly different seen from the clinical outcome result showing FPG (p=0.676), 2HPP (p=0.175), HbA1c (p=0.0445) and from the cost result (p=0.795). Furthermore, the research also shows that the average cost of 30-day medication of single human insulin was Rp3,190,997.43, while the one of analogue insulin was Rp3,188,832.35. In conclusion, the research finds out that if seen from the cost (p=0.795), the human and the analogue insulin were not significantly different.   
Cost Analysis from the Patient's Perspective and Economic Difficulties in Hemodialysis Patients at Fatmawati RSUP Jakarta Mawaddati Rahmi; Yusi Anggriani
Budapest International Research and Critics Institute (BIRCI-Journal): Humanities and Social Sciences Vol 4, No 3 (2021): Budapest International Research and Critics Institute August
Publisher : Budapest International Research and Critics University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33258/birci.v4i3.2514

Abstract

Chronic kidney disease is a global health problem with an increasing prevalence and incidence of kidney failure, has a poor prognosis and high costs. One way to overcome this high financing problem is of course by doing early treatment and for that, it is necessary to identify the risk factors of the disease. The purpose of this study was to examine the costs from the patient's perspective and the economic hardship experienced by the patient's family. The study used a case control method with a ratio of 1:1, where primary data were obtained through direct interviews with patients and/or their families. Based on the analysis, the average transportation cost required for one time hemodialysis is around Rp.12,000 - Rp.178,750, depending on vehicle type and vehicle mileage. Only 54 out of 100 hemodialysis patients need a companion with an average monthly cost of Rp.2,055,556. The cost of lost productivity per month in the study ranged fromRp.691,964 - Rp.1,942,308, depending on the patient's income. However, only 13% of patients experienced economic difficulties in the form of difficulty paying bills and daily needs. Other economic difficulties such as asking for help to selling assets were experienced by 25% of patients, and this was related to the length of time they underwent hemodialysis.
ANALISA KESESUAIAN PERESEPAN OBAT PASIEN BPJS KESEHATAN DENGAN FORMULARIUM NASIONAL DI PUSKESMAS KABUPATEN TANGERANG TAHUN 2016 Trisna Lestari; Yusi Anggriani; Dian Ratih Laksmitawati
Jurnal Farmagazine Vol 6, No 2 (2019): Jurnal Farmagazine
Publisher : STF Muhammadiyah Tangerang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47653/farm.v6i2.144

Abstract

lJaminan kesehatan adalah jaminan berupa perlindungan kesehatan agar peserta memperoleh manfaat pemeliharaan kesehatan dan perlindungan dalam memenuhi kebutuhan dasar kesehatan yang diberikan kepada setiap orang yang telah membayar iuran atau iurannya dibayar oleh pemerintah. Salah satu tempat pelayanan kesehatan tingkat pertama melalui sistem jaminan kesehatan adalah Badan Penyelenggara Jaminan Sosial Kesehatan (BPJS). Pemenuhan kebutuhan pasien berupa jenis obat yang harus tersedia pada peresepan dan pemesanan perlu disusun suatu daftar (formularium) dari semua obat yang ada di stok atau sudah tersedia. Dalam penggunaan obat di Puskesmas untuk pasien BPJS Kesehatan berpedoman pada standar terapi yang dikeluarkan oleh kementrian kesehatan yaitu formularium nasional (fornas) agar penggunaan obat pada pasien lebih rasional. Tujuan penelitian ini adalah untuk mengetahui kesesuaian peresepan obat pasien BPJS Kesehatan dengan Formularium Nasional berdasarkan kelas terapi dan kesesuaian ketersediaan item obat formularium nasional dengan daftar item obat formularium nasional di Puskesmas Kabupaten Tangerang Tahun 2016. Metode yang digunakan dalam penelitian ini adalah metode kualitatif non eksperimental yang bersifat deskriptif. Hasil penelitian Kesesuaian peresepan Obat dengan Formularium Nasional Berdasarkan Kelas Terapi dari 10 besar tertinggi sudah mencapai 100%, pada kesesuaian total peresepean yang di resepkan di puskesmas kabupaten Tangerang baru mencapai > 80%. Sedangkan rata-rata proprosi item obat formularium nasional dengan daftar item obat formularium nasional maish sangat rendah >50%. Kesimpulan penelitian ini adalah peresepan obat pasien BPJS Kesehatan dengan Formularium Nasional berdasarkan kelas terapi di puskesmas kabupaten Tangerang tahun 2016 sudah sesuai sedangkan ketersediaan item obat formularium nasional dengan daftar item obat formularium nasional masih belum sesuai. Kata kunci : BPJS Kesehatan, Peresepan, Formularium nasional
PENGARUH PROLANIS TERHADAP OUTCOME KLINIK PASIEN DIABETES MELITUS TIPE 2 DI PUSKESMAS KECAMATAN PULOGADUNG Herty Nur Tanty; Yusi Anggriani; Sahat Saragi
Farmasains : Jurnal Ilmiah Ilmu Kefarmasian Vol. 6 No. 1 (2019)
Publisher : Universitas Muhammadiyah Prof. DR. HAMKA

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (527.701 KB) | DOI: 10.22236/farmasains.v6i1.2978

Abstract

Prolanis merupakan program dari PT. Askes (Persero) dalam upaya penanganan penyakit kronis pada pasien DM tipe 2. Jumlah pasien DM yang tergabung di Prolanis setiap tahunnya terus bertambah akan tetapi tidak disertai dengan kontinuitas kunjungan. Berdasarkan data jumlah peserta prolanis DM tipe 2 di Puskesmas Kecamatan Pulogadung yang sudah mengikuti prolanis minimal 6 bulan sejumlah 284 pasien. Tujuan penelitian ini adalah untuk mendapatkan perbedaan outcome klinik pasien prolanis dibanding pasien non prolanis dan mendapatkan hubungan antara kepatuhan dengan outcome klinik. Penelitian ini menggunakan desain cross sectional dengan alur penelitian retrospektif sebelum dan sesudah pasien bergabung dengan prolanis. Data diperoleh dari rekam medik dan data kunjungan pasien dengan menggunakan teknik total sampling. Hasil penelitian menunjukkan adanya perbedaan outcome klinik pasien DM tipe 2 yang mengikuti prolanis dengan pasien DM tipe 2 yang tidak mengikuti prolanis (p<0,05). Hasil penelitian menunjukkan adanya hubungan antara tingkat kepatuhan kunjungan dengan outcome klinik pasien prolanis dan non prolanis (p<0.05).
Co-Authors Astrid Kartika Sari Chandra Widianti Desweri Muhareni Dian Ratih Laksmitawati Elisabeth Ninung Yuliarti Fredrick D. Purba Fredrick Dermawan Purba Herty Nur Tanty Manninda, Reise Mawaddati Rahmi Okpri Meila Prasasta Sutedjo Sahat Saragi Tarsinah Tarsinah Tri Kusumaeni Trisna Lestari